27 January
2025
N4 Pharma
plc
("N4
Pharma" or the "Company")
Investor
Webinar
N4 Pharma plc (AIM: N4P),
the biotech developing Nuvec®, its proprietary
gene delivery system to enable advanced therapies for cancer and
other diseases, is pleased
to announce that Nigel Theobald, Chief Executive Officer and Dr Alastair Smith,
Non-Executive Director, will hold an
investor presentation and Q&A session on Tuesday, 4 February 2025 at 9.30
am via the Investor Meet Company platform.
The presentation will provide an
overview of N4 Pharma and its lead programme, N4 101, a
dual-targeting, orally delivered RNA therapeutic
for inflammatory bowel disease.
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 9.00 am
the day before the meeting or at any time during the live
presentation.
Investors can sign up to Investor
Meet Company for free and add to meet N4 Pharma plc via:
https://www.investormeetcompany.com/n4-pharma-plc/register-investor
Investors who already follow N4
Pharma plc on the Investor Meet Company platform will
automatically be invited.
- Ends
-
For
more information please contact:
|
N4
Pharma plc
Nigel Theobald, Chief Executive
Officer
Luke Cairns, Executive
Director
|
Via N4 Pharma Investor Hub
Sign up at investors.n4pharma.com
|
|
Investor questions on this announcement
We also invite investors to ask
questions
on this announcement via our investor
hub
|
https://investors.n4pharma.com/link/VyENpe
|
|
SP
Angel Corporate Finance
LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate
Finance)
Vadim Alexandre/Abigail Wayne/Rob
Rees (Corporate Broking)
|
Tel: +44 (0) 20 3470 0470
|
|
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker/James Pope
|
Tel: +44 (0) 20 3657 0050
|
|
Northstar Communications Limited
Investor Relations
Sarah Hollins
|
Tel: +44 (0) 113 730 3896
|
About N4 Pharma
N4 Pharma is a biotech company
developing Nuvec®, its proprietary gene delivery system, to enable
advanced therapies for cancer and other diseases.
RNA therapeutics are set to impact
the treatment of a wide range of diseases and Nuvec® has several
key advantages for RNA gene delivery including the ability to
deliver multiple RNA therapies in a single particle, ease of
manufacturing, protection of the RNA
payload to allow for oral delivery, no unwanted immune response and
excellent stability and storage.
N4 Pharma is building out its
preclinical data set and working towards first-in-human clinical
data to support significant licensing deals for its Nuvec® platform
with gene therapy partners.
N4 Pharma's lead programme, N4 101,
is an oral anti-inflammatory product for inflammatory bowel disease
(IBD) which serves as a proof-of-concept programme showcasing all
the benefits of the Nuvec® platform. With
an estimated 10 million people globally suffering from Crohn's
disease and ulcerative colitis, the IBD treatment market was worth
$20.4bn in 2023 and is expected to grow by a CAGR of 3.9% to over
$27.6bn by 2030, driven by both increased incidences of the disease
and development of new treatments.
For further information on the
Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup.
